In the USA, the National Institutes of Health (NIH) has announced a new policy aimed at ensuring affordable access to medical products developed using government-owned technology.
The policy, a significant shift for the agency, will require drugmakers utilizing NIH patents to submit access plans that outline steps to support affordability and accessibility.
The move follows growing pressure from advocacy groups which have called for more robust action to ensure that taxpayer-funded medical advancements benefit the public.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze